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Abstract 
Background: The prognostic role of concomitant coronary artery disease (CAD) among 
patients undergoing transcatheter aortic valve implantation (TAVI) is still uncertain. 
Methods: Data from the Bern TAVI Registry and the Bern PCI Registry were analyzed. 
Patients with concomitant CAD undergoing TAVI (TAVI+CAD) were age- and gender-matched 
to the following two cohorts: patients without CAD undergoing TAVI (TAVI-noCAD) and 
patients with stable CAD undergoing percutaneous coronary intervention (CAD-noAS). Major 
adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of 
cardiovascular death, myocardial infarction, or cerebrovascular events, represented the 
primary endpoint at 1-year.  
Results: Out of 9,478 procedures performed between 2007 and 2013 (807 TAVI; 8,671 PCI), 
three cohorts, each including 248 subjects, were derived. At 1-year, MACCE were 
significantly increased among TAVI+CAD compared with TAVI-noCAD (16.8% vs. 9.8%, hazard 
ratio, HR, 1.75, 95% confidence intervals, CI, 1.06-2.89, p=0.030) and CAD-noAS patients 
(16.8% vs. 9.5%, HR 1.85, 95%CI 1.11-3.09, p=0.018) whereas no difference was found 
between TAVI-noCAD and CAD-noAS patients. The higher rate of MACCE among TAVI+CAD 
patients was mainly driven by an increased risk of cardiovascular mortality compared with 
the TAVI-noCAD (HR 1.86, 95%CI 1.03-3.36, p=0.040) and CAD-noAS cohorts (HR 2.29, 95%CI 
1.22-4.30, p=0.010). The 1-year rate of MACCE was similar between TAVI-noCAD and CAD-
noAS patients (9.8% vs. 9.5%, HR 1.05, 95%CI 0.59-1.87, p=0.86). 
Conclusions: Concomitant CAD in the setting of TAVI conveyed an increased risk of ischemic 
events and cardiovascular mortality at 1-year follow-up. 
Key words: coronary artery disease, transcatheter aortic valve implantation, prognosis, 
mortality  
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Introduction 
Aortic stenosis (AS) and coronary artery disease (CAD) frequently coexist owing to several 
common pathobiological factors.[1 2] Obstructive CAD has been associated with impaired 
clinical outcomes among patients undergoing surgical aortic valve replacement.[3 4] Yet, its 
prognostic role in the setting of transcatheter aortic valve implantation (TAVI) remains 
controversial.[5-7] Indeed, while some studies showed an increased risk of mortality and 
cardiovascular events after TAVI in the presence of concomitant CAD,[8-10] other studies 
provided neutral findings.[11-14] A lack of uniformity in the definition of CAD and a limited 
power are important limitations inherent to these studies.[15 16] In this context, the 
evaluation of the prognostic effect of concomitant CAD is also challenged by the risk profile 
of TAVI patients. Advanced age is likely to be a significant confounding factor with the 
potential to camouflage or rather heighten the risk of CAD-related outcomes after TAVI. 
Furthermore, the need for myocardial revascularization was a key exclusion criterion among 
pivotal trials that have established the role of TAVI in the management of severe AS.[15 16]  
Therefore, the aim of the present study was to define the prognostic role of CAD 
among TAVI patients by comparing the 1-year clinical outcomes of patients with 
concomitant CAD undergoing TAVI with age- and gender- matched cohorts of TAVI patients 
without CAD and patients with stable CAD in absence of AS who underwent percutaneous 
coronary intervention (PCI).  
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Methods 
Patient population and study cohort definitions 
The present study presents a three-arm, age- and gender-matched cohort design. All 
patients undergoing TAVI were included in the Bern TAVI registry (which is part of the Swiss 
TAVI Registry, NCT01368250) and all patients undergoing PCI were included in the Bern PCI 
registry (NCT02241291). All TAVI patients were evaluated for the presence of significant 
CAD, defined as history of surgical and/or percutaneous coronary revascularization, previous 
myocardial infarction (MI) and/or at least one significant lesion (diameter stenosis ≥50%) at 
the site of a major native coronary vessel or bypass graft by visual assessment in the 
coronary angiography performed within four weeks prior to TAVI. From the Bern PCI 
registry, only patients with stable CAD were deemed eligible for matching.  
The study complied with the declaration of Helsinki. Both registries were approved by the 
local ethics committee and all patients gave written informed consent to participate. 
 
Procedures  
The eligibility for TAVI was discussed within the local Heart Team and based on an extensive 
clinical and anatomical pre-operative assessment. Patients eligible for TAVI with 
concomitant CAD received PCI prior TAVI or during the same procedure on the basis of a 
consensus decision taking into account the myocardium at risk, the lesion complexity and 
symptom status. At this regard, internal guidelines, recommending preventive 
revascularization of significant proximal stenosis of major coronary arteries were followed. 
Functional ischemia testing was not routinely performed in view of the low diagnostic yield 
of stress testing in patients with aortic stenosis. 
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Patients in the TAVI cohort received either the Medtronic CoreValve bioprosthesis 
(Medtronic, Minneapolis, MN, USA), the Edwards Sapien transcatheter heart valve (Edwards 
LifeSciences, Irvine, CA, USA), or the Symetis Acurate TA aortic bioprosthesis (Symetis, 
Ecublens, Switzerland) through the femoral, transapical, or subclavian access, as previously 
described.[17] 
Current practice guidelines were followed in all patients in case of PCI.[18] Unfractionated 
heparin at a dose of at least 5,000 IU or 70-100 IU/kg was administered during the 
procedure. Management of antithrombotic medication consisted of dual antiplatelet 
therapy (DAPT) with acetylsalicylic acid and clopidogrel initiated before, at the time, or 
immediately after the procedure and recommended typically for 6 months after TAVI and for 
12 months after PCI (with or without TAVI). Acetylsalicylic acid was continued indefinitely 
after single or combined procedures. 
 
Clinical follow-up 
Patients included in the Bern TAVI registry were prospectively evaluated for the occurrence 
of adverse cardiac and cerebrovascular events in-hospital, at discharge and were contacted 
after 30 days and 12 months by means of clinic visit or standardized telephone interview. 
Patients in the Bern PCI registry were prospectively followed after the index PCI and were 
contacted after hospital discharge, during any unscheduled hospital visit or planned hospital 
visits (eg. staged procedures), and at 1 year after the index procedure. 
 
Study endpoints and definitions 
The primary study endpoint was a composite of major adverse cardiovascular and 
cerebrovascular events (MACCE), including cardiovascular death, myocardial infarction (MI), 
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or cerebrovascular events, at 1 year. Secondary endpoints were the individual components 
of the primary endpoint as well as all-cause mortality.  
Events occurring in patients undergoing TAVI were adjudicated by a clinical event committee 
consisting of interventional cardiologists and cardiac surgeons, according to the updated 
recommendations of the Valve Academic Research Consortium (VARC-2).  
For patients in the Bern PCI Registry, a clinical event committee adjudicated all adverse 
events. Cardiac death was defined as any death due to an immediate cardiac cause, 
procedure-related mortality, and death of unknown cause; MI was defined as peri-
procedural (<48h after PCI) in presence of electrocardiographic signs of ischemia and 
elevation of biomarkers of cardiac damage (increase in CK to more than twice the normal 
value with increased values of CK-MB fraction or troponin higher than usual) or spontaneous 
(>48h after PCI) if recurrent thoracic chest pain or ischemic equivalent symptoms occurred 
together with new ischemic electrocardiographic signs and biomarker elevation with rise 
and/or fall of cardiac biomarkers with at least one value above the 99th percentile upper 
reference limit. Stroke was defined as rapid development of clinical signs of focal or global 
disturbance of cerebral function lasting >24 hours with imaging evidence of acute, clinically 
relevant brain lesion. 
 
Statistical analysis 
Triple matching (1:1:1) of patients with TAVI and concomitant CAD (TAVI+CAD) vs. TAVI 
without CAD (TAVI-noCAD) vs. patients with stable CAD undergoing PCI (CAD-noAS) was 
performed. Triplets were matched according to gender and age (using a caliper of 0.02), 
randomly selected from a cohort of 795 TAVI patients from the Bern TAVI Registry and 3,528 
patients with stable CAD from the Bern PCI Registry (see Figure 1 for patient flow). Discrete 
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data were summarized as numbers and frequencies (%) whereas continuous data were 
presented as means ± standard deviations (SD). P-values for characteristics recorded at the 
patient level were calculated with un-paired t-tests, chi-square tests, or Fisher’s exact tests, 
except when specified. Statistical significance was considered at p <0.05. 
Clinical outcomes at 30 days and 1 year were expressed as counts and incidence rates 
computed according to the Kaplan–Meier method (censored at 30 days or 1 year, 
respectively). Hazard ratios were computed using Cox’s regressions for death, cardiovascular 
death, CVE, MI, and the composites of these endpoints. A landmark analysis at 30 days was 
performed to evaluate clinical events  through the different study cohorts during the early 
(0-30 days) and late (31-365 days) follow-up period. Statistical analyses were performed 
using Stata 13.1 (College Station, TX: StataCorp LP). 
 
Results 
Out of 9,478 procedures performed between 2007 and 2013 (807 TAVI; 8,671 PCI), three 
cohorts were derived as follows (Supplemental Figure 1): among 795 patients included in 
the Bern TAVI registry, CAD at baseline was identified in 514 (65%) patients (TAVI+CAD), 
leaving 281 (35%) patients without CAD (TAVI-noCAD). A total of 3,528 patients with stable 
CAD and without AS (CAD-noAS) underwent PCI and were included in the Bern PCI registry. 
After matching for age and gender (TAVI+CAD : TAVI-noCAD : CAD-noAS, 1 : 1 : 1), three 
cohorts including 248 patients each (62% male) were obtained. 
  
Published in final edited form as: Int J Cardiol. 2017 Sep 15;243:150-155. doi: 10.1016/j.ijcard.2017.05.071. 
9 
 
Baseline characteristics 
Table 1 shows baseline clinical characteristics of the three study cohorts (baseline features 
of the population prior to matching are detailed in Supplemental Table 1). TAVI+CAD and 
CAD-noAS patients had a similar risk profile, except for diabetes mellitus (33.5% vs. 18.5%, 
p<0.001), chronic renal failure (76.1% vs. 63.0%, p=0.002), and peripheral artery disease 
(19.8% vs. 11.3%, p=0.01) occurring at higher rate in the TAVI+CAD cohort. 
Hypercholesterolemia and arterial hypertension were more common among patients with 
CAD (TAVI+CAD and CAD-noAS) as compared with the TAVI-noCAD cohort. Regarding 
medication at discharge, CAD-noAS patients were more likely to receive DAPT, whereas TAVI 
patients more frequently had oral anticoagulants related to a higher prevalence of atrial 
fibrillation. 
Procedural details among patients undergoing TAVI with or without CAD are summarized in 
Supplemental Table 2.  
 
Clinical events throughout 1-year follow-up  
Rates of clinical outcomes across the study cohorts are reported in Table 2. At 30-day follow-
up, there was no significant difference for the primary endpoint of MACCE between the 
TAVI+CAD and TAVI-noCAD (7.3% vs. 5.6%, HR 1.30, 95% CI 0.64-2.61, p=0.47). Similarly, the 
risk of MACCE was not significantly different between the TAVI+CAD and the CAD-noAS 
groups (7.3% vs. 3.6%, HR 2.02, 95% CI 0.91-4.50, p=0.085). Cerebrovascular events occurred 
more frequently among TAVI patients, irrespective of CAD status (TAVI+CAD: 3.2%; TAVI-
noCAD: 4.4%, CAD-noAS: 0%; p=0.007 for both TAVI+CAD and TAVI-noCAD vs. CAD-noAS).  
At 1-year follow-up, MACCE were significantly increased among TAVI+CAD patients 
compared with TAVI-noCAD (16.8% vs. 9.8%, HR 1.75, 95% CI 1.06-2.89, p=0.030) and CAD-
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noAS patients (16.8% vs. 9.5%, HR 1.85, 95% CI 1.11-3.09, p=0.018) (Figure 1). This 
difference was mainly driven by a higher rate of cardiovascular mortality in the TAVI+CAD 
cohort relative to the TAVI-noCAD (12.7% vs. 7.0%, HR 1.86, 95% CI 1.03-3.36, p=0.040) and 
CAD-noAS groups (12.7% vs. 5.8%, HR 2.29, 95% CI 1.22-4.30, p=0.010). In TAVI patients 
without CAD, the rate of MACCE was similar to CAD patients undergoing PCI (9.8% vs. 9.5%, 
HR 1.05, 95% CI 0.59-1.87, p=0.86). 
The landmark analysis at 30-day follow-up showed that during the peri-procedural period, 
the MACCE rate was consistently higher among patients undergoing TAVI (irrespective of 
CAD) when compared with the CAD-noAS patient population. However, beyond 30 days, 
event curves were similar for TAVI-noCAD and CAD-noAS patients, whereas continuously 
diverging event curves were observed for TAVI+CAD patients throughout the first year 
(Figure 2). 
 
Clinical impact of PCI among patients undergoing TAVI 
A total of 110 patients (44.4%, 148 lesions) in the TAVI+CAD cohort underwent PCI prior or in 
the context of TAVI. Of these, more than half (54.3%) presented with significant lesions 
involving the proximal segments of the major epicardial coronary arteries (20.2% left 
anterior descending artery, 8.7% circumflex artery, 9.4% right coronary artery). 8 patients 
(7.3%) underwent PCI of the left main coronary artery and 12 (10.9%) patients had PCI of 
bypass grafts.  Supplemental Table 3 provides angiographic and procedural characteristics of 
TAVI+CAD and CAD-noAS patients. Compared with CAD-no AS, TAVI+CAD patients presented 
with significantly higher baseline and residual Syntax Score.  As shown in Supplemental 
Table 4, within the TAVI+CAD group, PCI was not associated with a significant difference in 
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MACCE during early (6.8% vs. 7.8%, PCI vs. no PCI, p= 0.75) and overall follow-up (14.9% vs. 
18.2%, PCI vs no PCI, p= 0.49). 
 
Discussion 
 
The salient findings of the present study investigating the prognostic role of CAD among 
patients undergoing TAVI are as follows:  
1. Patients with AS and concomitant CAD undergoing TAVI were at higher risk for 
MACCE and cardiovascular mortality compared with age-and gender-matched TAVI 
patients without CAD and patients with stable CAD undergoing PCI. 
2. In the absence of significant CAD, TAVI patients had a risk of ischemic adverse events 
that approached age- and gender-matched patients with stable CAD undergoing PCI. 
Although CAD is found in more than two thirds of patients considered for TAVI,[2] its 
prognostic role in this setting remains controversial. The presence of CAD, as defined by a 
history of percutaneous or surgical myocardial revascularization, has been reported to be 
associated with >10-fold higher risk of 30-day mortality.[12 16] If a history of previous MI 
and angiographic evidence of significant (>50%) coronary artery stenosis was considered to 
define relevant CAD, comparable survival rates were reported throughout 1-year follow-
up.[11] Moreover, at long-term follow-up, CAD was an independent predictor of mortality 
among patients included in the UK-TAVI Registry.[19] 
However, two aspects should be factored when evaluating the association of concomitant 
degenerative AS and CAD. First, both conditions are closely associated with ageing, which in 
turn predicts mortality.[20 21] Second, gender has an independent prognostic role among 
patients undergoing TAVI [22-25] and a significant treatment interaction between TAVI and 
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surgery has been reported in randomized trials.[16 26] In view of these considerations, the 
comparison across the three cohorts matched for age and gender was meant to account for 
these relevant factors. Indeed, a significantly increased risk of ischemic events emerged 
among TAVI patients with concomitant CAD relative to their counterpart without CAD, and 
this risk was also higher compared with patients with stable CAD undergoing PCI. 
There are several pathophysiological mechanisms which may explain the adverse association 
between CAD and severe AS. Arguably, the presence of ischemic myocardium, 
notwithstanding a successful relief of the valvular stenosis, may circumvent reverse left 
ventricular remodeling and the improvement of systolic and diastolic function.[27 28] Such 
mechanisms could play a role particularly in patients with a history of previous MI. On the 
other hand, excessive myocardial hypertrophy, which typically develops in response to 
sustained pressure overload by a narrowed aortic valve, may precipitate the ischemic 
burden associated with a significant, flow-limiting, coronary stenosis. Consistently, in the 
current study, the higher risk of MACCE observed among patients with concomitant CAD 
undergoing TAVI was mainly related to a heightened risk of cardiovascular mortality.  
The comparison of TAVI patients with concomitant CAD against those with stable CAD in the 
absence of AS may inform more comprehensively on the natural history of CAD and AS. In 
the TAVI+CAD cohort, a greater number of patients presented with diabetes mellitus, 
peripheral artery disease or chronic renal failure compared with subjects with stable CAD in 
absence of AS. Thus, patients with both CAD and severe AS may harbor a more extensive 
burden of atherosclerotic disease. Furthermore, TAVI+CAD patients presented with a 
significantly higher Syntax score at baseline, suggesting a greater extent and complexity of 
CAD than CAD-no AS patients that was not offset by PCI. Residual Syntax score, indeed, 
remained higher in TAVI+CAD relative to their counterpart without valve disease. An indirect 
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proof of the negative impact of significant CAD is that clinical outcomes of TAVI patients 
without CAD were similar to those of patients with stable CAD undergoing PCI, particularly 
outside the peri-procedual period. Therefore, the prognosis of TAVI patients, when 
compared against a reference group of stable CAD patients undergoing PCI, seemed to be 
largely dominated by the presence of additional CAD rather than other factors. 
Overall, in our cohort, 40% of TAVI patients with CAD underwent PCI, a proportion somewhat 
higher compared with other reports. Nevertheless, this resulted from a standardized internal 
protocol that consists of performing coronary revascularization on the basis of the Heart Team 
decision and taking into account the overall risk profile of the patients, the clinical 
presentation and the severity of CAD as assessed by visual estimation. TAVI and PCI of 
angiographically significant (≥ 50%) stenoses in major epicardial vessels are frequently 
performed in the same session. However, a staged procedure strategy (some days prior to 
TAVI or alternatively in the early post-procedural phase) is adopted to minimize contrast load 
in patients at higher risk for acute kidney injury. Of note, we found that concomitant PCI did 
not result in a lower rate of clinical events after TAVI. This observation should not imply that 
PCI is dispensable in TAVI candidates, rather indicates that the adverse prognosis featuring 
the TAVI+CAD group was still noticeable on top of contemporary treatment. In this respect, 
several randomized trials designed to investigate revascularization modalities and the optimal 
timing of intervention in patients undergoing TAVI are ongoing (ISRCTN75836930, 
NCT01586910, NCT02797158). As such, the present study highlights the magnitude of risk 
conferred by CAD among TAVI patients demanding a major research effort to mitigate the 
influence of CAD in this setting. 
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Limitations 
The results of this study should be interpreted in the context of the following limitations. 
First, the study population was based on the experience of a single center. Secondly, the 
presence of myocardial ischemia was not routinely collected and therefore it was not 
considered in the definition of CAD among TAVI patients. Thirdly, the study cohorts were 
matched on the basis of age and gender. Therefore, a possible imbalance due to residual 
confounders factors cannot be excluded. Fourth, the analysis included elderly subjects, 
considered to be at increased risk for surgical aortic valve replacement. As a consequence, 
the present findings could not be extended to lower risk categories of TAVI. 
 
Conclusions 
In an age- and gender- matched cohort study, the presence of CAD among TAVI patients 
conferred an adverse prognosis in terms of major adverse events and cardiovascular 
mortality. In the absence of CAD, TAVI patients incurred in a rate of ischemic events that was 
similar to patients with stable CAD undergoing PCI during 1-year follow-up.   
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FIGURE LEGENDS 
 
Figure 1– Cumulative incidence of adverse cardiovascular outcomes (composite of 
cardiovascular death, CVE, or MI) through one year in the three study cohorts - TAVI+CAD 
(red), TAVI-noCAD (orange) and CAD-noAS (blue).  
AS: Aortic stenosis; CAD: Coronary artery disease; CVE: Cerebrovascular events; MI: Myocardial infarction; PCI: 
Percutaneous coronary intervention; TAVI: Transcatheter aortic valve implantation. 
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Figure 2 Cumulative incidence of MACCE (composite of cardiovascular death, CVE, or MI) 
during the first 30 days after procedure and thereafter for patients in the TAVI+CAD (red), 
TAVI-noCAD (orange) and the CAD-noAS cohort (blue).  
AS: Aortic stenosis; CAD: Coronary artery disease; CVE: Cerebrovascular events; MI: Myocardial infarction; PCI: 
Percutaneous coronary intervention; TAVI: Transcatheter aortic valve implantation. 
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Table 1. Baseline clinical characteristics       
       
  TAVI+CAD TAVI-noCAD  CAD-noAS TAVI+CAD  vs. TAVI-noCAD  
TAVI+CAD 
 vs.CAD-noAS 
TAVI-noCAD  
vs. CAD-noAS 
  n= 248 n= 248 n= 248   p-value   p-value p-value  
           
Age (years)  82.1 ± 5.6  81.9 ± 5.7 81.9 ± 5.6 0.72 0.62 0.89 
Female gender, n(%) 154 (62.1%) 154 (62.1%) 154 (62.1%) 1.00 1.00 1.00 
Body mass index (kg/m2)  26.1 ±  4.7 26.3±5.4 26.7 ±  4.7 0.73 0.22 0.42 
Diabetes mellitus, n(%)   83 (33.5%) 60 (24.2%) 46 (18.5%) 0.029 <0.001 0.15 
     Insulin treated, n(%)   33 (13.3%)  22  (8.9%) 14  (5.6%) 0.15 0.005 0.22 
 Hypercholesterolemia, n(%) 190 (76.6%)  111 (44.8%) 163 (65.7%) <0.001 0.010 <0.001 
 Hypertension, n(%) 222 (89.5%) 193 (77.8%) 209 (84.3%) 0.001 0.11 0.08 
 Peripheral artery  disease, n(%) 49 (19.8%)  25 (10.1%) 28 (11.3%) 0.004 0.013 0.77 
 Previous CVE, n(%) 26 (10.5%) 18  (7.3%) 24  (9.7%) 0.27 0.88 0.42 
 Renal failure (GFR<60ml/min/1.73m2) 188 (76.1%) 168 (67.7%) 145 (63.0%) 0.045 0.002 0.29 
 Atrial fibrillation, n(%)  69 (34.2%) 66 (32.2%) 25 (23.8%) 0.75 0.068 0.14 
 Previous MI, n(%) 56 (22.6%) - 50 (20.2%)  0.58  
 Previous CABG, n(%)   30 (13.6%) - 23  (9.3%)  0.15  
 Previous PCI, n(%) 90 (36.3%) - 78 (31.5%)  0.30  
 Left ventricular ejection fraction(%)  54.0 ± 15.4 55.5 ±1 5.2 56.2 ± 14.1 0.31 0.12 0.59 
Medication at discharge         
 Aspirin, n(%) 213 (88.4%)  200 (81.6%) 237 (96.7%) 0.042 <0.001 <0.001 
 Clopidogrel, n(%) 181 (75.1%) 167 (68.2%) 213 (86.9%) 0.11 0.001 <0.001 
 Beta-blockers, n(%)   122 (65.2%) 121 (59.3%) 157 (64.1%) 0.25 0.84 0.32 
 ACE inhibitors or ATII antagonists, n(%)   133 (71.1%) 145 (71.1%) 179 (73.1%) 1.00 0.67 0.67 
 Statins, n(%)  133 (71.1%)  77 (37.7%) 198 (80.8%) <0.001 0.022 <0.001 
 Oral anticoagulants,  n(%)  68 (28.2%)  82 (33.5%) 38 (15.5%) 0.24 0.001 <0.001 
       
Depicted are means ± SD with p-values from t-tests, or counts (%) with p-values from Fisher's tests (two categories) or chi square tests (more than two categories). p-values for pairwise comparisons are unadjusted for multiple   
comparisons. ACE: Angiotensin- converting- enzyme; AS: Aortic stenosis; ATII: Angiotensin II receptor; CABG: Coronary artery bypass graft; CAD: Coronary artery disease; CVE: Cerebrovascular event (stroke or TIA); GFR: Glomerular 
filtration rate; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; TAVI: Transcatheter aortic valve implantation. 
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Table 2. Clinical outcomes at 30-day and 1 year of follow-up 
                          
          TAVI+CAD vs. TAVI-noCAD   
TAVI+CAD  
vs. CAD-noAS    
TAVI-noCAD 
 vs. CAD-noAS  
  TAVI+CAD TAVI-noCAD 
CAD-
noAS   HR (95% CI) 
p-
value   HR (95% CI) 
p-
value   HR (95% CI) 
p-
value 
  n= 248 n= 248 n= 248                   
30-Day follow-up                         
All cause death, n(%) 11 (4.4) 10 (4.0) 7 (2.8)   1.12 (0.47-2.63) 0.80   1.58 (0.61-4.08) 0.34   1.42 (0.54-3.74) 0.48 
Cardiovascular death, n(%) 11 (4.4) 8 (3.2) 5 (2.0)   1.39 (0.56-3.47) 0.47   2.21 (0.77-6.36) 0.14   1.59 (0.52-4.87) 0.41 
Cerebrovascular events, n(%) 8 (3.2) 11 (4.4) 0 (0.0)   0.73 (0.29-1.82) 0.50   17.00 (0.99-292.94)* 0.007   
23.00 (1.36-
388.17)* 0.007 
Myocardial infarction, n(%) 1 (0.4) 0 (0.0) 6 (2.4)   3.00 (0.12-73.29) 1.000   0.17 (0.02-1.38) 0.096   0.08 (0.00-1.41) 0.12 
Cardiovascular death, CVE, or 
MI, n(%) 18 (7.3) 14 (5.6) 9 (3.6)   1.30 (0.64-2.61) 0.47   2.02 (0.91-4.50) 0.085   1.56 (0.68-3.61) 0.30 
1-year follow-up                         
All cause death, n(%) 41 (16.6) 31 (12.5) 27 (10.9)   1.35 (0.85-2.15) 0.21   1.57 (0.97-2.56) 0.067   1.16 (0.69-1.95) 0.57 
Cardiovascular death, n(%) 31 (12.7) 17 (7.0) 14 (5.8)   1.86 (1.03-3.36) 0.040   2.29 (1.22-4.30) 0.010   1.23 (0.60-2.49) 0.57 
Cerebrovascular events, n(%) 9 (3.7) 12 (4.9) 2 (0.9)   0.75 (0.32-1.79) 0.52   4.61 (1.00-21.35) 0.051   6.11 (1.37-27.29) 0.018 
Myocardial infarction, n(%) 5 (2.2) 0 (0.0) 10 (4.1)   11.00 (0.61-197.87) 0.061   0.51 (0.17-1.48) 0.22   0.05 (0.00-0.85) 0.30 
Cardiovascular death, CVE, or 
MI, n(%) 41 (16.8) 24 (9.8) 23 (9.5)   1.75 (1.06-2.89) 0.030   1.85 (1.11-3.09) 0.018   1.05 (0.59-1.87) 0.86 
                          
Depicted are counts (incidence rates % from Kaplan Meier life-tables). 
Hazard Ratios HR (95% CI) from Cox's Regressions. * Continuity corrected Risk ratios (95% CI) with p-value from Fisher's test. AS: Aortic stenosis; CAD: Coronary artery disease; CVE: Cerebrovascular events; MI: 
Myocardial infarction; PCI: Percutaneous coronary intervention; TAVI: Transcatheter aortic valve implantation. 
 
